Psoriasis Club
  • Forum
  • Home
  • Portal
  • Member List
  • Psoriasis Score
  • PQOLS
  • What is psoriasis
  • Search
  • Help
Hello Guest, Welcome To The Psoriasis Club Forum. We are a self funded friendly group of people who understand.
Never be alone with psoriasis, come and join us. (Members have more privileges)
wave
Login Register
Login
Username:
Password:
Lost Password?
 
Psoriasis Club › HealthHealth Boards › Psoriasis In The News v
1 2 3 4 5 … 49 Next »

Otezla (apremilast) quality of life, efficacy, and safety study

Threaded Mode
Otezla (apremilast) quality of life, efficacy, and safety study
Fred Online
I Wanted To Change the World But Got Up Far Too Late.
Moderator
Posts: 57,003
Threads: 3,553
Joined: Aug 2011
Gender: Male
Location: France
Psoriasis Score: 1
Psoriatic Arthritis Score: 1
PQOLS: 2
Treatment: Bimzelx / Coconut Oil
#1
News  Mon-31-10-2022, 13:40 PM
Otezla (apremilast) significantly improved skin-related quality of life in patients with psoriasis.

Quote:
Introduction/Background:
Manifestations of psoriasis in special areas are difficult to treat and are associated with a high disease burden and significant quality of life (QoL) impairment. Topical therapies may be inadequate for these patients, necessitating systemic treatment.

Objective:
The objective of EMBRACE was to evaluate the impact on QoL, efficacy, and safety of apremilast 30 mg BID in patients with limited skin involvement with plaque psoriasis manifestations in special areas and impaired QoL.

Methods:
EMBRACE (NCT03774875) was a phase 4, randomized, placebo-controlled, multinational study. Patients had plaque psoriasis not controlled by topical therapy; lack of response, contraindication, or intolerance to conventional first-line systemic therapy; psoriasis in ≥1 special area (including visible locations, scalp, nails, genital areas, or palmoplantar areas); Psoriasis Area and Severity Index (PASI) ≥3 to ≤10; and Dermatology Life Quality Index (DLQI) >10. The primary endpoint was DLQI response (≥4-point reduction) at Week 16.

Results:
Of 277 randomized patients (apremilast: n=185; placebo: n=92), 221 completed Week 16 (apremilast: n=152; placebo: n=69). The primary endpoint (≥4-point reduction in DLQI at Week 16) was met by significantly more patients receiving apremilast (73.3%) versus placebo (41.3%; P<0.0001). Significantly greater improvement in affected body surface area (BSA) and PASI was observed with apremilast versus placebo at Week 16. There were also significantly greater improvements with apremilast versus placebo in itch numeric rating scale (−2.5 vs −0.9, P<0.0001) and skin discomfort/pain visual analog scale (−21.5 vs −5.4, P=0.0003) and greater achievement of Patient Benefit Index ≥1 (77% vs 40%, P<0.0001) at Week 16. No new safety signals were observed.

Conclusions:
Apremilast significantly improved skin-related QoL in patients with limited skin involvement with plaque psoriasis in special areas and highly impaired QoL. The safety profile was consistent with prior apremilast studies.

Source: onlinelibrary.wiley.com

*Early view funding unknown

Otezla
Quote
mataribot Offline
100 + Member I Just Cant Stop !

100 + Member I Just Cant Stop !
Posts: 1,137
Threads: 36
Joined: Jun 2013
Gender: Male
Location: USA
Treatment: >_<
#2
Tue-01-11-2022, 03:14 AM (This post was last modified: Tue-01-11-2022, 03:22 AM by mataribot. Edited 1 time in total.)
I am not a fan of systemic treatment for a small limited amount of psoriasis. From my experience, it just makes it worse in the long run if treatment is discontinued. There are non steroid creams on the market and more on the way. I would think that would be a better option try first.

And besides, outside the US, Otezla isn't going to be the first choice of treatment - it's to expensive and there are a lot more cheaper options.
Quote
« Next Oldest | Next Newest »


Possibly Related Threads…
Thread Author Replies Views Last Post
News Psoriasis and cardiovascular study Fred 2 465 Fri-24-03-2023, 21:41 PM
Last Post: Kat
News Tremfya vs Stelara Italian study Fred 2 497 Fri-27-01-2023, 12:39 PM
Last Post: Fred
News Delphi study into generalized pustular psoriasis Fred 0 416 Sat-07-01-2023, 14:17 PM
Last Post: Fred
News Siliq / Kyntheum real life data Fred 0 411 Sat-24-12-2022, 21:53 PM
Last Post: Fred
News Efficacy and safety of orismilast for psoriasis Fred 0 485 Fri-09-12-2022, 13:24 PM
Last Post: Fred



Users browsing this thread: 1 Guest(s)
    Contact us | Login | Register | Home | Cookies/GDPR | RSS Syndication | Portal | Types Of Psoriasis | Psoriasis Score | Members Only Boards
    Copyright © 2010 - 2023 Psoriasis Club All Rights Reserved | Founded May 2010 | Psoriasis Club Is Self Funded Without Sponsors Or Donations | Software by MyBB | Social
Linear Mode
Threaded Mode